Mayo Clinic developed an AI that analyzes routine pathology slides to classify meningiomas and predict recurrence risk, reducing dependency on advanced genetic testing.
Key Details
- 1Study published in The Lancet Digital Health by Mayo Clinic researchers.
- 2AI models analyze standard H&E slides to classify meningiomas and predict recurrence.
- 3Approach relies on images already used in clinical care, not on expensive genetic tests.
- 4Dataset included tissue samples, images, and clinical data from 672 patients.
- 5AI predictions remained valuable beyond traditional clinical factors like tumor grade or patient age.
- 6Further prospective studies are needed before routine clinical adoption.
Why It Matters
This work shows how imaging AI can extend the power of pathology slides, making advanced tumor insights more universally accessible even where genetic testing isn't available. It holds promise for improved, personalized cancer care using existing imaging workflows.
Source
EurekAlert
Related News
•EurekAlert
MSKAI Unveils AI Tool for Embryo Cell Analysis and Imaging-Driven Cancer Insights
MSK researchers employ AI and advanced imaging to reveal cancer mechanisms and track embryonic development at the single-cell level.
•EurekAlert
AI-Driven Home Sensors Enable Privacy-Preserving Health Emergency Detection
Researchers have developed an AI-powered home monitoring system using radar and thermal sensors to detect health emergencies and support elderly independent living.
•EurekAlert
New Study Urges 'Green AI' Practices in Medical Imaging and Healthcare
A new review highlights the urgent need for sustainable AI practices in healthcare, with emphasis on environmental impacts from applications like medical imaging.